Coca-Cola European Partners enters binding agreement to acquire Coca-Cola Amatil acquisition after completing due diligence

AstraZeneca maintains guidance after profit jumps in Q3 on strength in cancer drugs

AstraZeneca maintains guidance after profit jumps in Q3 on strength in cancer drugs

StockMarketWire.com – Coca-Cola European Partners said it completed its due diligence and entered into a binding scheme implementation deed to acquire Coca-Cola Amatil.

Under the terms of the deal, the company would offer to acquire 69.2% of the entire existing issued share capital of CCL, which is held by shareholders other than the Coca-Cola Company for $12.75 per share in cash.

Coca-Cola European Partners also entered into a deal with Coca-cola to acquire the remaining 30.8% stake, which was conditional upon the implementation of the scheme.

CCL had reaffirmed that they intend to unanimously recommend the scheme to independent shareholders.

Under the co-operation and sale deed, Coca-Cola will be entitled to receive A$9.57 per share in cash for part of their shareholding, which comprises 10.8% of CCL’s Amatil shares. CCEP will acquire all of KO’s remaining 20% shareholding in CCL for A$10.75 per share,

At 10:04am: [
LON:CCEP] share price was -0.15p at 30.75p

Story provided by StockMarketWire.com

Derwent London touts improving rent collection, pledges to work with occupiers as second lockdown gets underway

Derwent London touts improving rent collection, pledges to work with occupiers as second lockdown gets underway